CVIA 082 Study
Vaccine Preventable Diseases
A Phase II, Observer-blinded, Randomized, Active-controlled Study to Examine the Immunogenicity and Safety of Rotarix® and RV3-BB when Coadministered/Boosted with Trivalent P2-VP8 Subunit Rotavirus Vaccine Candidate in Healthy Infants in South Africa.
Rationale
Diarrhea is the second-leading cause of infectious disease death worldwide among children under the age of five. Rotavirus is the leading cause of severe diarrhea, resulting in an estimated 215,000 (range: 197,000–233,000) deaths in 2013 which corresponds to 3.4% of all deaths in children.
Investigators
- Prof Lee Fairlie, Principal Investigator
- Faeezah Patel
- Elizea Horne
- Mrinmayee Dhar
Latest Update
September 2023
For more details about the CVIA 082 Study please email rhicomms@wrhi.ac.za
